Cellectis (CLLS) Change in Working Capital (2015 - 2026)
Cellectis (CLLS) posted quarterly Change in Working Capital of -$19.5 million for Q1 2026, down 195.99% year-over-year from $20.3 million in Q1 2025, and down 151.97% quarter-over-quarter from $37.5 million in Q4 2025.
Analysis
Cellectis (CLLS) Change in Working Capital (2015 - 2026) Analysis & Trends
Cellectis' Change in Working Capital history runs 12 years deep, the most recent figure standing at -$19.5 million for Q1 2026.
- In Q1 2026, Change in Working Capital fell 195.99% year-over-year to -$19.5 million; the TTM figure through Mar 2026 stood at $28.7 million (up 165.23% YoY), while the FY2025 annual figure was $41.6 million, up 177.5% from the prior year.
- Change in Working Capital for Q1 2026 stood at -$19.5 million, down from $37.5 million in the prior quarter.
- The five-year high for Change in Working Capital was $70.1 million in Q4 2022, with the low at -$22.2 million in Q1 2022.
- The 5-year median for Change in Working Capital is -$16.0 million (2023), against an average of -$4.4 million.
- The sharpest annual moves came in 2024 and 2025: Change in Working Capital plunged 606.61% in 2024, then jumped 426.92% in 2025.
- Cellectis' Change in Working Capital stood at $70.1 million in 2022, then slumped by 94.22% to $4.1 million in 2023, then slumped by 606.61% to -$20.5 million in 2024, then surged by 282.66% to $37.5 million in 2025, then plunged by 151.97% to -$19.5 million in 2026.
- Business Quant data shows CLLS's Change in Working Capital at -$19.5 million in Q1 2026, $37.5 million in Q4 2025, and $17.0 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Working Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Cellectis | 321.90 Mn | 155.05 Mn | - | -17.29 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -17.29 Mn |
| Mar 31, 2026 | -19.50 Mn |
| Dec 31, 2025 | -10.30 Mn |
| Sep 30, 2025 | 16.96 Mn |
| Jun 30, 2025 | -6.31 Mn |
| Mar 31, 2025 | -6.59 Mn |
| Dec 31, 2024 | -4.11 Mn |
| Sep 30, 2024 | -5.19 Mn |
| Jun 30, 2024 | -11.65 Mn |
| Mar 31, 2024 | -16.29 Mn |
| Dec 31, 2023 | -20.67 Mn |
| Sep 30, 2023 | -18.69 Mn |
| Jun 30, 2023 | -18.20 Mn |
| Mar 31, 2023 | -16.03 Mn |
| Dec 31, 2022 | 146,000.00 |
| Sep 30, 2022 | -20.90 Mn |
| Jun 30, 2022 | -21.32 Mn |
| Mar 31, 2022 | -22.21 Mn |
| Dec 31, 2021 | 17.76 Mn |
| Sep 30, 2021 | -29.67 Mn |